Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its Market Outperform rating and $86 price target for CRISPR Therapeutics AG (NASDAQ:CRSP) on November 11. The firm discussed positive findings from CRISPR’s American Heart Association presentation on CTX310, targeted at ANGPTL3 for a variety of cholesterol issues.

Following the weekend data presentation, Citizens voiced optimism regarding CRISPR’s in-vivo projects. The firm noted some major catalysts, including in-vivo cardiovascular and alpha-1 antitrypsin deficiency updates in 2026, as well as a pediatric review for Casgevy at the American Society of Hematology meeting in 2025.

In addition, CRISPR’s third-quarter Casgevy sales fell short of forecasts, totaling $17 million compared to a consensus estimate of $41 million, with infusions falling from 16 in the second quarter to 10 in the current quarter. Nonetheless, CRISPR Therapeutics AG (NASDAQ:CRSP) remains confident about the Casgevy launch, citing increased cell collection numbers (45 vs. 25 in the second quarter) and a new reimbursement arrangement with Italy.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology that uses its proprietary gene sequencing platform to develop precise treatments for diseases that require DNA modification.

While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.